Nurses, surgery workers had highest COVID-positive rates when the pandemic was young

Healthcare workers were infected with COVID-19 in greater percentages than the general population, and nurses were hardest hit of all, during the early days of the pandemic, according to a study conducted at Rutgers University and published in BMC Infectious Diseases.

The researchers used data collected last spring to establish baseline infection rates from early on in the public health crisis. The journal published their report online Nov. 16.

Overall, of 829 participants, 7.3% of healthcare workers (40 people) and 0.4% of non-healthcare workers—one person—were COVID-positive in March.

Of the 41 who tested positive, 14 individuals (34%) reported symptoms.  

Looking at the 546 healthcare workers recruited for the study, all of whom work at one of two hospitals in New Jersey, the Rutgers team found infection rates varying among roles as follows:

  • Nurses—11.1% (25 of 225)
  • Resident or fellow physicians—3.1% (3 of 98)
  • Attending physicians—1.8% (2 of 112)
  • All others—9.0% (10 of 111)

The team also broke out infection rates by where the workers are stationed within the hospital:

  • Operating room—9.7% (13 of 134)
  • Emergency department—8.2% (20 of 245)
  • Designated COVID unit—7.9% (5 of 63)
  • Medical floor—4.9% (9 of 185)
  • ICU—2.2% (4 of 192)
  • All other locales—5.5% (14 of 255)

In a news item posted by Rutgers, Emily Barrett, PhD, a biostatistician and epidemiologist, comments that these initial results show that, at the beginning of the pandemic, “the higher rate of infection observed in urban northern New Jersey areas, like Newark, was also reflected in the healthcare workers serving those communities.”

In the study’s discussion section, the authors say they’ll follow up with the study cohort longitudinally to obtain “novel incidence and exposure data as well as greater statistical power to understand factors associated with new infections.”

The study is available in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.